Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.50 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 5/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 5/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509883 | 1.00 | TBXAS1 (0.50) | TBXAS1GPR52TRPV1HRH1PLA2G1B | |
| SCHEMBL11149396 | 0.93 | GPR52 (0.53) | TBXAS1GPR52TRPV1HRH1 | |
| SCHEMBL16289717 | 0.85 | TRPV1 (0.64) | TBXAS1GPR52TRPV1 | |
| SCHEMBL16288651 | 0.85 | TRPV1 (0.64) | TBXAS1GPR52TRPV1 | |
| SCHEMBL16288652 | 0.85 | TRPV1 (0.64) | TBXAS1GPR52TRPV1 | |
| SCHEMBL16289982 | 0.85 | TRPV1 (0.64) | TBXAS1GPR52TRPV1 | |
| SCHEMBL597782 | 0.85 | TRPV1 (0.64) | TBXAS1GPR52TRPV1 | |
| SCHEMBL16289718 | 0.85 | TRPV1 (0.64) | TBXAS1GPR52TRPV1 | |
| SCHEMBL1150822 | 0.83 | TRPV1 (0.61) | TBXAS1GPR52TRPV1 | |
| SCHEMBL1009881 | 0.83 | TRPV1 (0.61) | TBXAS1GPR52TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | LANTHEUS MEDICAL IMAGING, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | MMP1, MMP10, MMP8 | TBXAS1 1102/4885GPR52 4759/4885TRPV1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.